血清miR-203、miR-217表达与急性髓系白血病患者预后的关系

摘要 目的：探究血清miR-203、miR-217表达与急性髓系白血病(AML)患者预后的关系。方法：选择2010年4月至2014年4月我院诊治的101例AML患者作为AML组，AML组根据治疗效果进一步分为完全缓解组和复发组，选择同期在我院体检的101例健康者作为健康组。采用荧光定量PCR检测各组的血清miR-203、miR-217表达水平，分析血清miR-203、miR-217表达水平与患者临床病理特征的关系，采用Kaplan-Meier法分析不同血清miR-203、miR-217表达水平AML患者的预后。结果：与健康组相比，AML组的血清miR-203、miR-217表达水平明显更低（P<0.05）。与完全缓解组相比，复发组的血清miR-203、miR-217表达水平明显更低（P<0.05）。血清miR-203表达水平与AML患者白细胞计数相关（P<0.05），而血清miR-217表达水平与AML患者血小板计数相关（P<0.05）。血清miR-203相对高表达和miR-217相对高表达的AML患者5年生存率分别高于血清miR-203相对低表达和miR-217相对低表达患者（Log Rank ^miR-203 =17.870，Log Rank ^miR-217 =28.926，均P=0.000）。结论：血清miR-203、miR-217的表达水平与AML密切相关，检测血清miR-203、miR-217表达水平可能有助于评估AML患者的预后。

Relationship between the Expression of Serum miR-203 and miR-217 and the Efficacy and Prognosis of Patients with Acute Myeloid Leukemia

ABSTRACT Objective: To investigate the relationship between the expression of serum miR-203 and miR-217 and the efficacy and prognosis of patients with acute myeloid leukemia. Methods: 101 patients with acute myeloid leukemia treated in our hospital from April 2010 to April 2014 were selected as the AML group. The AML group was further divided into the complete remission group and the relapse group according to the treatment effect, and 101 healthy patients who underwent physical examination in our hospital during the same period were selected as the healthy group. The expression levels of serum miR-203 and miR-217 in each group were detected by fluorescence quantitative PCR, and the relationship between the expression levels of serum miR-203 and miR-217 and the clinicopathological features of the patients was analyzed. Kakaplan-Meier method was used to analyze the survival of AML patients with different serum miR-203 and miR-217 levels. Results: Compared with the healthy group, the serum miR-203 and miR-217 levels in the AML group were significantly lower(P<0.05). Compared with the complete response group, the serum miR-203 and miR-217 levels in the relapse group were significantly lower(P<0.05). Serum miR-203 levels were associated with leukocyte count in AML patients (P<0.05), while serum miR-217 levels were associated with platelet count in AML patients(P<0.05). The 5-year survival rate of AML patients with relatively high expression of serum miR-203 and miR-217 was higher than those with relatively low expression of serum miR-203 and miR-217, respectively (Log Rank _miR-203 =17.870, Log Rank _miR-217 =28.926, all P=0.000). Conclusion: The expression levels of serum miR-203 and miR-217 are closely related to AML. Detection of serum miR-203 and miR-217 expression levels might be helpful in evaluating the efficacy and prognosis of AML patients.